Modality
Radioligand
MOA
AuroraAi
Target
TROP-2
Pathway
RAS/MAPK
DravetFTDMeso
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
Apr 2022
→ Nov 2025
Phase 2Current
NCT06479413
190 pts·FTD
2022-04→2025-11·Completed
190 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-284mo agoPh2 Data· FTD
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2025-11-28 · 4mo ago
FTD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06479413 | Phase 2 | FTD | Completed | 190 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 |